48.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$48.17
Aprire:
$47.88
Volume 24 ore:
3.02M
Relative Volume:
1.22
Capitalizzazione di mercato:
$117.19B
Reddito:
$43.23B
Utile/perdita netta:
$6.79B
Rapporto P/E:
12.08
EPS:
4.0051
Flusso di cassa netto:
$9.17B
1 W Prestazione:
-0.19%
1M Prestazione:
-2.34%
6M Prestazione:
+0.10%
1 anno Prestazione:
-3.01%
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
SNY
Sanofi Adr
|
48.37 | 116.71B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-12-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-03-21 | Iniziato | Goldman | Neutral |
| 2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Reiterato | Argus | Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Downgrade | Stifel | Buy → Hold |
| 2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Ripresa | Morgan Stanley | Overweight |
| 2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Downgrade | UBS | Buy → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Sell |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Iniziato | Bernstein | Outperform |
| 2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
| 2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
| 2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
Regeneron Just Moved From Underperform To Buy - Benzinga
FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug - Benzinga
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - Sahm
Where is Sanofi (SNY) Headed According to Wall Street? - Finviz
Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz
Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm
Our Environmental Impact - Sanofi
Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
Sanofi (SNY) sees slight pessimism from analysts - MSN
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech
SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets
Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz
JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):